Table 4.
Gastrointestinal tract bleeding among DOAC using patients.
| Gastrointestinal tract bleeding | |||||||
|---|---|---|---|---|---|---|---|
| Concurrent statin | No. of PQs | No. of events | Crude incidence rate (per 1,000 person-year) (95% CI) | Adjusted incidence rate (per 1,000 person-year) (95% CI) | Adjusted IRR (95% CI) | Adjusted IRD (per 1,000 person-year) (95% CI) | |
| All | No statin | 332259 | 3533 | 43 (41.43–44.56) | 38.5 (36.68–40.42) | 1 | |
| All intensity | 238923 | 1679 | 28.4 (26.95–29.94) | 28.4 (26.93–29.92) | 0.74 (0.69–0.79) | −10.12 (−12.51 to −7.73) | |
| High-intensity | 79266 | 605 | 30.9 (28.34–33.77) | 30.9 (28.30–33.72) | 0.82 (0.74–0.90) | −6.97 (−10.25 to −3.69) | |
| Low-to-moderate-intensity | 165474 | 1129 | 27.6 (25.89–29.39) | 27.6 (25.87–29.36) | 0.71 (0.66–0.77) | −11.13 (−13.68 to −8.58) | |
| Male | No statin | 190084 | 1796 | 38.13 (36.23–40.12) | 34.13 (31.89–36.52) | 1 | |
| All intensity | 135304 | 865 | 25.8 (23.97–27.76) | 25.76 (23.94–27.72) | 0.75 (0.68–0.83) | −8.37 (−11.35 to −5.39) | |
| High-intensity | 45017 | 315 | 28.31 (25.10–31.94) | 28.25 (25.04–31.87) | 0.83 (0.73–0.96) | −5.61 (−9.74 to −1.47) | |
| Low-to-moderate-intensity | 93569 | 579 | 24.97 (22.85–27.30) | 24.93 (22.80–27.25) | 0.73 (0.65–0.82) | −9.17 (−12.35. −6.00) | |
| Female | No statin | 141669 | 1735 | 49.56 (47.04–52.22) | 46.44 (43.36–49.74) | 1 | |
| All intensity | 103070 | 810 | 31.82 (29.51–34.32) | 31.83 (29.51–34.33) | 0.69 (0.62–0.76) | −14.46 (−18.47 to −10.45) | |
| High-intensity | 34017 | 290 | 34.61 (30.46–39.32) | 34.59 (30.44–39.30) | 0.76 (0.66–0.88) | −11.01 (−16.44 to −5.57) | |
| Low-to-moderate-intensity | 71558 | 546 | 30.91 (28.24–33.84) | 30.91 (28.24–33.83) | 0.67 (0.59–0.75) | −15.53 (−19.77 to −11.29) | |
DOAC, direct oral anticoagulant; PQ, person-quarter; CI, confident interval; IRR, incidence rate ratio; IRD, incidence rate difference.